Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $1.92 HKD
Change Today +0.02 / 1.05%
Volume 386.0K
503 On Other Exchanges
Hong Kong
As of 4:01 AM 10/9/15 All times are local (Market data is delayed by at least 15 minutes).

lansen pharmaceutical holdin (503) Snapshot

Previous Close
Day High
Day Low
52 Week High
06/25/15 - $4.65
52 Week Low
09/7/15 - $1.47
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for LANSEN PHARMACEUTICAL HOLDIN (503)

Related News

No related news articles were found.

lansen pharmaceutical holdin (503) Related Businessweek News

No Related Businessweek News Found

lansen pharmaceutical holdin (503) Details

Lansen Pharmaceutical Holdings Limited, an investment holding company, develops, produces, and sells specialty prescription western pharmaceuticals for the treatment of rheumatic diseases in the People’s Republic of China and internationally. It operates through Specialty Pharmaceuticals, Plant Extract and Healthcare Products, and Other Pharmaceuticals segments. The company’s rheumatic specialty prescription western pharmaceuticals comprise Pafulin, which includes total glucosides of white peony capsules; Hepai, a leflunomide tablet; and mycophenolate mofetil dispersible tablets. It also offers gynecological and dermatology products, as well as Chinese medicine extracts and healthcare products. In addition, the company distributes human-like collagen dressing products, which are used for the suppression and mitigation of skin inflammation responses caused by various reasons, such as dermatitis, sensitive skin, acne, and laser therapy under the Kefumei brand in China. The company was founded in 2001 and is headquartered in Ningbo, the People’s Republic of China. Lansen Pharmaceutical Holdings Limited is a subsidiary of Cathay International Holdings Limited.

880 Employees
Last Reported Date: 09/9/15
Founded in 2001

lansen pharmaceutical holdin (503) Top Compensated Officers

Chief Executive Officer, Executive Director a...
Total Annual Compensation: $365.0K
Compensation as of Fiscal Year 2014.

lansen pharmaceutical holdin (503) Key Developments

Lansen Pharmaceutical Holdings Limited Appoints Hou Song as Chief Financial Officer, Effective from 16 September 2015

Lansen Pharmaceutical Holdings Limited announced that Mr. Hou Song will join the company on 11 September 2015 and has been appointed as Chief Financial Officer of the company with effect from 16 September 2015. Mr. Hou, has over 15 years of experience in finance, accounting and corporate management in Hong Kong and in mainland China. Prior to joining the company, Mr. Hou worked in The Wing Fat Printing Co., Limited from 2008 to 2015 as Chief Financial Officer of Wing Fat's operating subsidiary; and lately, the Head of Corporate Management Department at Wing Fat's Hong Kong headquarters responsible for overall corporate management including development strategy, budget management, internal control and audit.

Lansen Pharmaceutical Holdings Limited Announces Executive Changes

The board of directors of Lansen Pharmaceutical Holdings Limited announced that Mr. Mui Chi Hung will resign as company secretary and chief financial officer of the company, with effective from September 16, 2015, as he has to pursue his other career opportunities. The board announced that Mr. Leung Tsz Chun, the finance manager of the company, has been appointed as company secretary of the company with effective from September 16, 2015. Mr. Leung has over 7 years of experience in audit, finance and accounting. Prior to joing the company in 2014, he worked in KPMG, Hong Kong for six years as Audit Manager.

Lansen Pharmaceutical Holdings Limited Recommends Interim Dividend for the Six Months Ended June 30, 2015, Payable on or Before September 25, 2015

The Directors of Lansen Pharmaceutical Holdings Limited recommend the payment of an interim dividend of 3.44 HKD cents per share for the six months ended June 30, 2015 to the shareholders listed in the register of members of the company as at the close of business on September 16, 2015. The interim dividend will be distributed on or before September 25, 2015 to the shareholders. The company paid interim dividend of 9.54 cents per share for the same period a year ago.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
503:HK $1.92 HKD +0.02

503 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for 503.
View Industry Companies

Industry Analysis


Industry Average

Valuation 503 Industry Range
Price/Earnings 8.0x
Price/Sales 0.9x
Price/Book 0.9x
Price/Cash Flow 8.0x
TEV/Sales NM Not Meaningful

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact LANSEN PHARMACEUTICAL HOLDIN, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at